Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 16/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24008892 | 0.81 | TSHR (0.34) | TSHR | |
| SCHEMBL24837454 | 0.78 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL24008890 | 0.77 | TSHR (0.32) | TSHR | |
| SCHEMBL26400807 | 0.75 | CYP2D6 (0.38) | CYP2D6SMN1; SMN2CYP3A4TSHRCYP2C9 | |
| SCHEMBL25826575 | 0.75 | PIK3CD (0.44) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1PIK3CD | |
| SCHEMBL18926689 | 0.74 | CYP2D6 (0.68) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL13683387 | 0.73 | CYP2D6 (0.61) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL14706855 | 0.72 | CYP2D6 (0.66) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL13683386 | 0.71 | CYP2D6 (0.59) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL22477427 | 0.71 | CYP2D6 (0.59) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | CYP2D6 2442/4885SMN1; SMN2 820/4885CYP3A4 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.